Skip to main content

Table 1 Baseline characteristics of RCTs included in this review

From: Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis

Trial Trial design NOAC Proportion of included patients Sample size, n Mean age (years) Number of female (%) Mean CHADS2 score TTR Number of TOE (%) Ref.
NOAC VKA NOAC VKA NOAC VKA NOAC VKA   NOAC VKA
ARISTOLE subgroup Post-hoc analysis of a double-blinded RCT Apixaban 171 (31.7%) 265 275 67 67 72 (27%) 74 (27%) 1.8 1.9 59.0% 86 (32%) 85 (31%) [32]
RE-LY subgroup Post-hoc analysis of an open-label RCT Dabigatran 110 mg BD 1183 (53.8%) 647 664 NR NR NR NR NR NR NR 168 (26%) 86 (13%) [33]
Dabigatran 150 mg BD 672 NR NR NR 161 (24%)
ENSURE-AF Open-label RCT to determine events after CV Edoxaban 415 (20.9%) 1095 1104 64 64 374 (34%) 382 (35%) 2.6 2.6 70.8% 589 (54%) 594 (54%) [31]
X-VeRT Open-label RCT to determine events after CV Rivaroxaban 628 (41.8%) 1002 502 65 65 275 (27%) 135 (27%) NR* NR* NR 410 (41%) 218 (43%) [34]
  1. ARISTOTLE apixaban for the prevention of stroke in subjects with atrial fibrillation trial, BD twice daily, CV cardioversion, ENSURE-AF the edoxaban vs. warfarin in subjects undergoing cardioversion of atrial fibrillation study, NOAC non-vitamin K antagonist oral anticoagulants, NR not reported, NR* not reported as mean value, RCT randomised controlled trial, Ref. Reference, RE-LY randomised evaluation of long-term anticoagulation therapy trial, TOE transesophageal echocardiography, TTR time in therapeutic range, X-VeRT explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in patients with non-valvular atrial fibrillation scheduled for cardioversion